Literature DB >> 24070816

'Double trouble': diagnostic challenges in Duchenne muscular dystrophy in patients with an additional hereditary skeletal dysplasia.

Sandra Donkervoort1, Alice Schindler, Carolina Tesi-Rocha, Allison Schreiber, Meganne E Leach, Jahannaz Dastgir, Ying Hu, Ami Mankodi, Kathryn R Wagner, Neil R Friedman, Carsten G Bönnemann.   

Abstract

Duchenne muscular dystrophy (DMD) is caused by mutations in Dystrophin and affects 1 in 3600-6000 males. It is characterized by progressive weakness leading to loss of ambulation, respiratory insufficiency, cardiomyopathy, and scoliosis. We describe the unusual phenotype of 3 patients with skeletal dysplasias in whom an additional diagnosis of DMD was later established. Two unrelated boys presented with osteogenesis imperfecta due to point mutations in COL1A1 and were both subsequently found to have a 1 bp frameshift deletion in the Dystrophin gene at age 3 and age 15 years, respectively. The third patient had a diagnosis of pseudoachondroplasia caused by a mutation in the COMP gene and was found to have a deletion of exons 48-50 in Dystrophin at age 9. We discuss the atypical presentation caused by the concomitant presence of 2 conditions affecting the musculoskeletal system, emphasizing aspects that may confound the presentation of a well-characterized disease like DMD. Additional series of patients with DMD and a secondary inherited condition are necessary to establish the natural history in this "double trouble" population. The recognition and accurate diagnosis of patients with two independent genetic disease processes is essential for management, prognosis, genetic risk assessment, and discussion regarding potential therapeutic interventions.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Double trouble; Duchenne muscular dystrophy; Genetic counseling; Ostoegenesis imperfecta

Mesh:

Substances:

Year:  2013        PMID: 24070816      PMCID: PMC5030769          DOI: 10.1016/j.nmd.2013.08.003

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  27 in total

1.  Duplications in the DMD gene.

Authors:  S J White; A Aartsma-Rus; K M Flanigan; R B Weiss; A L J Kneppers; T Lalic; A A M Janson; H B Ginjaar; M H Breuning; J T den Dunnen
Journal:  Hum Mutat       Date:  2006-09       Impact factor: 4.878

Review 2.  Emerging drugs for Duchenne muscular dystrophy.

Authors:  Vinod Malik; Louise R Rodino-Klapac; Jerry R Mendell
Journal:  Expert Opin Emerg Drugs       Date:  2012-06       Impact factor: 4.191

3.  Detection of germline mosaicism in two Duchenne muscular dystrophy families using polymorphic dinucleotide (CA)n repeat loci within the dystrophin gene.

Authors:  Verónica Ferreiro; Irene Szijan; Florencia Giliberto
Journal:  Mol Diagn       Date:  2004

4.  Deletion mapping in Xp21 for patients with complex glycerol kinase deficiency using SNP mapping arrays.

Authors:  Christopher M Stanczak; Zugen Chen; Yao-Hua Zhang; Stanley F Nelson; Edward R B McCabe
Journal:  Hum Mutat       Date:  2007-03       Impact factor: 4.878

5.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

6.  Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort.

Authors:  Kevin M Flanigan; Diane M Dunn; Andrew von Niederhausern; Payam Soltanzadeh; Eduard Gappmaier; Michael T Howard; Jacinda B Sampson; Jerry R Mendell; Cheryl Wall; Wendy M King; Alan Pestronk; Julaine M Florence; Anne M Connolly; Katherine D Mathews; Carrie M Stephan; Karla S Laubenthal; Brenda L Wong; Paula J Morehart; Amy Meyer; Richard S Finkel; Carsten G Bonnemann; Livija Medne; John W Day; Joline C Dalton; Marcia K Margolis; Veronica J Hinton; Robert B Weiss
Journal:  Hum Mutat       Date:  2009-12       Impact factor: 4.878

Review 7.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

8.  Origins and early descriptions of "Duchenne muscular dystrophy".

Authors:  Kenneth L Tyler
Journal:  Muscle Nerve       Date:  2003-10       Impact factor: 3.217

9.  Long-term benefit from prednisone therapy in Duchenne muscular dystrophy.

Authors:  G M Fenichel; J M Florence; A Pestronk; J R Mendell; R T Moxley; R C Griggs; M H Brooke; J P Miller; J Robison; W King
Journal:  Neurology       Date:  1991-12       Impact factor: 9.910

10.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.

Authors:  Maria Kinali; Virginia Arechavala-Gomeza; Lucy Feng; Sebahattin Cirak; David Hunt; Carl Adkin; Michela Guglieri; Emma Ashton; Stephen Abbs; Petros Nihoyannopoulos; Maria Elena Garralda; Mary Rutherford; Caroline McCulley; Linda Popplewell; Ian R Graham; George Dickson; Matthew J A Wood; Dominic J Wells; Steve D Wilton; Ryszard Kole; Volker Straub; Kate Bushby; Caroline Sewry; Jennifer E Morgan; Francesco Muntoni
Journal:  Lancet Neurol       Date:  2009-08-25       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.